Phentermine HCl Capsules
Overview of Phentermine HCl Capsules
Dosage Strength
Commercial: 30 mg CapsuleCommercial: 37.5 mg Tablet
Compounded: 45 mg Capsule
Compounded: 30 mg Slow Release Capsule
Compounded: 37.5 mg Slow Release Capsule
Compounded: 45 mg Slow Release Capsule
General Information
Phentermine is an oral sympathomimetic amine used as an adjuvant in the treatment of exogenous obesity for a brief period of time (e.g., 8—12 weeks). Phentermine has similar pharmacologic effects as amphetamines. The FDA approved phentermine resin complex in 1959, however it is no longer available in the United States. The FDA authorized phentermine hydrochloride in 1973. There was increasing interest in phentermine in combination with another anorectic, fenfluramine, for the treatment of obesity and substance misuse in the mid-1990s, although there is little scientific evidence to support this practice. The FDA issued a ‘Dear Health Care Professional’ letter on July 8, 1997, warning physicians about the development of valvular heart disease and pulmonary hypertension in women receiving the combination of fenfluramine and phentermine; fenfluramine was later withdrawn from the US market in the fall of 1997. The combination of phentermine and other anorectic medications for obesity has not been studied and is not recommended. In May 2011, the FDA authorized Surrenza, an orally disintegrating tablet containing phentermine hydrochloride, for the treatment of exogenous obesity. 1
References
1.Suprenza (phentermine hydrochloride) package insert. Cranford, NJ: Akrimax Pharmaceuticals; 2011 Oct.
2.Adipex-P (phentermine hydrochloride tablets and capsules) package insert. Sellersville, PA: Teva Pharmaceuticals; 2013 Jan.
3.Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006;318:604-610.
4.Adipex-P (phentermine hydrochloride tablets and capsules) package insert. Sellersville, PA: Teva Pharmaceuticals; 2013 Jan.
5.Suprenza (phentermine hydrochloride) package insert. Cranford, NJ: Akrimax Pharmaceuticals; 2011 Oct.
6.Phentermine hydrochloride package insert. Newtown, PA: KVK-Tech Inc; 2010 April.
7.Steiner E, Villen T, Hallberg M, et al. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 1984;27:123-4.
8.Meridia® (sibutramine) package insert. North Chicago, IL: Abbott Laboratories; 2003 Oct.
9.Fastin® (phentermine) package insert. Philadelphia, PA: Beecham Laboratories; 1987 Oct.
10.Dexedrine® (dextroamphetamine) package insert. Research Triangle Park, NC; GlaxoSmithKline; 2007 Mar.
11.Kulig K, Moore LL, Kirk M, et al. Bromocriptine-associated headache: possible life-threatening sympathomimetic interaction. Obstet Gynecol. 1991;78:941—3.
12.Cesamet™ (nabilone) package insert. Costa Mesa, CA: Valeant Pharmaceuticals International; 2006 May.
13.Foltin RW, Fischman MW, Pedroso JJ, et al. Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 1987;28:459—94.
14.Azilect (rasagiline mesylate) tablets. Kansas City, MO: Teva Neurosciences, Inc.; 2014 May.
15.Elavil® (amitriptyline) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2000 Dec.
16.Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996;15:135—57.
17.Halothane, USP package insert. North Chicago, IL: Abbott Laboratories; 1998 Mar.
18.Tenuate® (diethylpropion hydrochloride) package insert. Bridgewater, NJ: Aventis Pharmaceuticals; 2003 Nov.
19.Strattera® (atomoxetine) package insert. Indianapolis, IN: Eli Lilly and Company; 2008 May.
20.Serevent® Diskus (salmeterol xinafoate inhalation powder) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2008 Mar.
21.Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
22.O’Neill PM, Peterson, CA. Weight Loss and Depression in Overweight/Obese Subjects With a History of Depression Receiving Phentermine and Topiramate Extended-Release. Presented at the 166th Annual Meeting of the American Psychiatric Association (APA
23.Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phentermine. J Clin Psychopharmacol 1996;16:189—90.
24.Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006;318:604-610.
25.Qsymia (phentermine and topiramate extended-release) package insert. Mountain View, CA: Vivus, Inc.; 2014 Sept.
26.Allison DB, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330-342.
27.Brintellix (vortioxetine tablets) package insert. Deerfield, IL: Takeda Pharmacueticals America, Inc.; 2014 Jul.
28.Suprenza (phentermine hydrochloride) package insert. Cranford, NJ: Akrimax Pharmaceuticals; 2011 Oct.
29.Phentermine hydrochloride package insert. Newtown, PA: KVK-Tech Inc; 2010 April.
30.Lomaira (phentermine hydrochloride) package insert. Newton, PA: KVK-Tech, Inc.; 2016 Sept.
31.Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38:292-298.
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.